



Day 1 Summary

Linus Chuang MD MPH MS
Professor, Gynecologic Oncology
Icahn School of Medicine at Mount Sinai
New York NY

Cervix Cancer Education Symposium, January 2017, Mexico




- Welcome and opening remarks Dr. Meneses and Dra. Gallardo
- Introduction of participants
 - One third are conducting clinical trials
- What's CCRN Dr. Gaffney
 - Improve education in care and clinical research
 - Supports 4 ongoing clinical trials
 - Develop new trials
- Cervical cancer: a global perspective Dr. Poveda
 - Calls for prevention and to improve survival as a priority




- Radiation Hope Dr. Fisher
 - Provide and update radiation equipment in developing countries through fund raising
- Varian: emerging markets Mr. Pollatz
 - Treating cervical cancer without brachytherapy has an inferior survival
 - Provides technical and educational supports
- Elect: emerging markets Ms. de Bekker
 - Promising results from image guided brachytherapy




- Advaxis and Stendhal presentations: Mr. Duke
 - Develop targeted immunotherapies
 - Listeria generated T cell responses
 - AXAL Phase 2 trial and AIM2CERV trial in Cervical Cancer
- IGCS perspective- Dr. Covens
 - New web site
 - New education programs
 - Calls for new members to join IGCS
 - Calls for new editor-in-chief for IJGC



- IAEA perspective Dr. Wahab
 - Global cancer plan aims at decreasing death from cancer
 - Develop guidelines
 - Supports education, quality assurance, clinical trials etc
- Management of cervical cancer in resource limited settings
 - ASCO and NCCN resource stratified guidelines
- Reports of survey Dr. Gaffney
 - Clinical practice information



- Global cervical cancer Dr. Trimble
 - Trials: 1 vs 2 doses of HPV vaccination, new ablative technology
 - Clinical research initiative for global health
 - Affordable cancer technology
 - A cost effective IMRT delivery for LMIC
- Good clinical Practice and QA compliance Dr. Bacon
- Beyond platinum: concurrent chemotherapy in cervix cancer Dr. Dueñas González
 - Gemcitabine plus cisplatin chemoradiotherapy followed by BCT and adjuvant gemcitabine/cisplatin chemotherapy improved survival outcomes with increased but clinically manageable toxicity when compared with standard treatment.



- Neoadjuvant chemotherapy in cervix cancer Dra. Gomez
 - Benefits and review of trials
- SLN in cancer of the cervix Dr. Plante
 - Clinical application of SLN detection
- Role of surgery in cervical cancer Dr. Cantu
 - Surgery is not going away
 - More research is needed



- Biomarkers in cervix cancer Dr. Plasencia
 - Gene signatures to predict responses
 - Transcriptome analysis helps distinguish clinical responses
- Immunotherapy in treatment of cervix cancer Dr. Mileshkin
 - Adoptive cellular transfer
 - Active immunotherapy
 - Axalimogene Filolisbac (discussed further today)
 - Check point inhibitors
 - Ipilimumab, Nivolumab, Pemprolizumab